Abstract:
:Death still occurs in Hodgkin's disease (HD) patients with advanced stages, but also in early stages. Therefore, the identification of the population of HD patients who would best benefit from an intensification of treatment is a prerequisite in all stages. The best known prognostic factors are bulky mediastinum, B symptoms, and visceral involvement in advanced HD and, in early HD, the number of nodal areas. No satisfactory combination of these factors can clearly identify a group of patients requiring high dose- and potentially risky therapy. Therefore only a very small subgroup of patients with advanced disease (less than 5% of them) calls for intensified regimens, which makes randomized trials very difficult. A large data base, accrued through a cooperative effort and the addition of early stages to advanced stages, would help to clarify the prognostic analysis. In addition, the patient population needs to be selected on the basis of the best therapeutic approach to-date. The analysis parameter should take into account only the failures due to the tumor progression as opposed to those due to a combination of tumor progression and early plus late toxicities. Three successive steps are required to achieve the goal of high-risk patient's treatment optimization. The first is to define, on a well-defined tumor-risk scale, the kind of results that are to be considered as "unacceptable" when up-to-date conventional strategies are applied. The second is to infer the size of the "high-risk" population, in inverse ratio to the severity of the risk accepted for "normal-risk" patients. The third is to tailor the iatrogenic risk, ie the intensity of the high-dose treatment, to the size of the target population and to the anti-tumor benefit that is anticipated. Obviously, the definition of these parameters belongs to the medical decision-makers. Nevertheless, the availability of a quantified tumor-risk scale would allow to elaborate a reliable strategy in patients at risk for failure, lethal toxicity and unbearable health expenses. A collection of adequate recent trial is proposed through the Third International Symposium on Hodgkin's lymphoma in Köln (21-23 September 1995). This effort will be pursued through the International Data Base for Hodgkin's Disease (IDHD). Newer and more efficient strategies may then be designed.
journal_name
Bull Cancerjournal_title
Bulletin du cancerauthors
Carde Psubject
Has Abstractpub_date
1995-08-01 00:00:00pages
637-49issue
8eissn
0007-4551issn
1769-6917pii
0007-4551(96)80879-4journal_volume
82pub_type
杂志文章,评审abstract::Improved techniques for inducing heat: ultrasound, microwaves, diathermy with different application modalities, capable of producing localized superficial or deep, regional or total body hyperthermia have been responsible for the multiplication of clinical trials. These studies have confirmed the tumoricidal effect of...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:
更新日期:1981-01-01 00:00:00
abstract::Tamoxifen is widely used nowadays in the management of breast cancer, having established its efficacy in this indication, especially for postmenopausal patients with ER-positive breast tumours. However, tamoxifen has recently been recognized as carcinogenic for the human endometrium, probably with an effect of duratio...
journal_title:Bulletin du cancer
pub_type: 临床试验,杂志文章,多中心研究,评审
doi:
更新日期:1997-01-01 00:00:00
abstract::Thyroid carcinoma on struma ovarii (TCSO) is a rare ovarian tumour, derivate from monodermic teratomas. It represents about 0.01% of overall ovarian tumours and 5 to 10% of struma ovarii. The diagnosis is histologic and retrospective after pelvic surgery; radiographic imaging being unspecific. Because of its rarity, t...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1016/j.bulcan.2017.11.014
更新日期:2018-03-01 00:00:00
abstract:BACKGROUND:Depression is an important symptom for many palliative care patients but is rarely identified. It's known to reduce quality of life and impact on palliation of physical symptom. These physical symptoms can be improved by an adequate treatment of depression. Many depressed cancer patients are not treated due ...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1684/bdc.2011.1310
更新日期:2011-02-01 00:00:00
abstract::Since the first published correlations around the years 1975 between estrogen and progesterone receptors and response to hormone therapy, numerous data have modified our insight on hormone dependency. For instance, it is now well established that tumors are not "receptor positive" or "receptor negative" but contain va...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::During the last decade, inhibitors of the vascular endothelial growth factor (VEGF) were developed for the treatment of cancer. Many anti-VEGF are available but the issue is still the same: to inhibit the effect of the VEGF on their receptors. There are two main classes, depending on the mechanism of action by blockin...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1016/j.bulcan.2016.05.005
更新日期:2016-07-01 00:00:00
abstract:INTRODUCTION:Adapted physical activity (APA) is recognized as an effective supportive care for asthenia and quality of life in oncology. Before an APA program was organized, the feasibility of such a program was evaluated among the patients. METHODS:Descriptive, prospective, semi-qualitative, single-center study over ...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1016/j.bulcan.2017.11.011
更新日期:2018-03-01 00:00:00
abstract::Pain is frequent in the course of cancer and can have negative consequences on patients quality of life. The great majority of patients can be helped by simple treatments. The prescription of morphine (M) must be preceded by some explanations. In order to verify the reality of these explanations, a study was done in a...
journal_title:Bulletin du cancer
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1998-04-01 00:00:00
abstract::The physician-patient relationship has three main stakes : creating a high-quality inter-personal relationship, exchanging information and decision-making. The achievement of these stakes implies that the physician and the patient are able to reach specific communicational objectives. The aim of this paper is to revie...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:
更新日期:2006-04-01 00:00:00
abstract::Bleomycin (BLM), a currently used anticancer drug, crosses the plasma membrane poorly. Electropermeabilization allows a defined number of BLM molecules to enter directly into the cell cytoplasm. Such a procedure has revealed that BLM is endowed with a very high intrinsic cytotoxicity. Here we show that when several mi...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1994-12-01 00:00:00
abstract:CONTEXT:The "Standards, Options and Recommendations" (SOR) collaborative project was initiated in 1993 by the Federation of the French Cancer Centres (FNCLCC), with the 20 French Regional Cancer Centres, several French public university and general hospitals, as well as private clinics and medical specialty societies. ...
journal_title:Bulletin du cancer
pub_type: 指南,杂志文章,实务指引
doi:
更新日期:2002-04-01 00:00:00
abstract::Taxoids and platinum derivatives display a true activity against many types of solid tumors. Their relatively non overlapping toxicity profiles and their different mechanisms of action made their combination attractive. Actually, the frequency and the severity of the toxicity appeared schedule-dependent. Thus, cisplat...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:
更新日期:2000-08-01 00:00:00
abstract:AIM:Harvesting of the "sentinel lymph node" (SLN) as identified by lymphoscintigraphy (LSG) is becoming increasingly important in the staging of patients with malignant melanoma. The purpose of the current study was to determine whether the appearance time of the LSG had a prognostic value in predicting metastasis diss...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:2004-07-01 00:00:00
abstract:INTRODUCTION:The diagnosis of chronic myeloid leukemia is based on the presence of translocation t(9,22). Additional cytogenetic abnormalities may exist at diagnosis and have prognostic value. The authors evaluated the relationship between these additional chromosomal abnormalities, clinical presentation, and therapeut...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1016/j.bulcan.2019.03.013
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:To establish the recommended dose (RD) of the thymidylate-synthase inhibitor ZD9331 administered with irinotecan (CPT-11) in patients with pretreated metastatic colorectal cancer, and to assess toxicity profile, pharmacokinetics (PK), and anti-tumor activity in a phase I/II open, multicenter, intrapatient ch...
journal_title:Bulletin du cancer
pub_type: 临床试验,杂志文章,多中心研究
doi:
更新日期:2004-12-01 00:00:00
abstract::Since 1976 to 1978 inclusive, 465 patients with primary breast cancers underwent whole body analogical scintiscans, 456 numerical scans, and 453 were X-rayed. Ninety per cent received axillary node ablation, 62% presented adenopathies of which a third were capsular ruptures and 54% were T3 and T4. In 53 patients, the ...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1987-01-01 00:00:00
abstract::Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies. Morphologically, these tumors are undifferentiated histopronostic grade 3 carcinomas, identified in clinical practice according to their immunophenotype "triple zero" (estrogen, progesterone a...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1684/bdc.2010.1062
更新日期:2010-03-01 00:00:00
abstract::Targeted therapy against the EGF receptor was shown to be effective in a subgroup of patients with KRAS wild-type colorectal cancer. Therefore, cetuximab (Erbitux) or panitumumab (Vectibix) obtained the authorization by the EMEA restricted to patients with KRAS wild-type tumours. KRAS mutational testing has become par...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1684/bdc.2009.0996
更新日期:2009-12-01 00:00:00
abstract::The endothelins (ET1, ET2, ET3) are a family of peptides that exert vasoactive and mitogenic effects. ETs bind to at least two subtypes of receptors: the ETA subtype is ET1 selective whereas the ETB subtype binds ET1, ET2 and ET3. By RT-PCR, we detected ETA receptor mRNA and ETB receptor mRNA in leiomyoma and in homol...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1999-09-01 00:00:00
abstract::For more than a decade, Transforming Growth Factor Beta (TGF beta) has been intensively studied. Such studies have led to the identification of many related polypeptides which constitute the TGF beta family. These factors modulate many animal cell processes such as cell cycle progression, differentiation, adhesion, mi...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:
更新日期:1994-12-01 00:00:00
abstract::In industrialized countries cervical cancer has decreased over the past decades. This, thanks to wide spread screening campaigns of precancerous lesions and microinvasive diseases through regular pap smears starting from the beginning of sexual activity. The diagnostic is realized earlier, thus increasing the rate of ...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:
更新日期:1998-11-01 00:00:00
abstract::The authors analyse 123 cases of carcinoma of the uterine cervix treated by radiotherapy, with CEA radio-immuno-assay performed before treatment then each time patients are seen in follow-up. The CEA level is positive in 35 per cent of the cases with a mean value of 21 per cent for stage I, 36 per cent for stage II an...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1979-01-01 00:00:00
abstract::Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin. We performed an observational prospective study on 101 patients evaluating the efficacy of aprepitant in the clinical conditions of use of cisplatin, out of context of clinical trial. W...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1684/bdc.2008.0819
更新日期:2009-02-01 00:00:00
abstract::In medical oncology, how can we be sure that the right drug is being administered to the right patient at the right time? The implementation of quality assurance criteria is important in medical oncology, in order to ensure that the patient receives the best treatment safely. There is very little literature about qual...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1684/bdc.2014.1968
更新日期:2014-05-01 00:00:00
abstract::Breast cancer (BC) has the highest incidence rate in women in industrialized countries. Statistically, it is estimated that one out of 10 women will develop BC during her life. Evidence is accumulating for the role of ion channels in the development of cancer. Most studied ion channels in BC are K(+) channels, which a...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1684/bdc.2012.1595
更新日期:2012-06-01 00:00:00
abstract:FOCAL TREATMENT AND SYSTEMIC THERAPY IN METASTATIC KIDNEY CANCER:COMPLEMENTARY APPROACHES: To treat metastatic renal cell carcinoma, therapies used are with an oral intake, for the vast majority, and have many side effects that may compromise observance. Strategies of drug holiday have been studied and, in case of an i...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1016/S0007-4551(18)30376-X
更新日期:2018-12-01 00:00:00
abstract::Innovation in radiotherapy should meet multiple challenges, both technically, biologically, clinically and socially. Scientific, technological and biological advances have resulted in major changes in the implementation, indications, and therapeutic index of radiotherapy over the last century. Based on technical innov...
journal_title:Bulletin du cancer
pub_type: 杂志文章,评审
doi:10.1016/j.bulcan.2018.12.006
更新日期:2019-01-01 00:00:00
abstract::Whereas medicine is progressing in illness treatment that used to be incurable, physicians are still faced with treatment failure. Hippocrates used to say: "primum non nocere" [1]. When the patient cannot expect benefit from potentially aggressive care, current or possible treatments have to be challenged to leave jus...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:10.1684/bdc.2009.0910
更新日期:2009-07-01 00:00:00
abstract::Between October 1987 and June 1992, 244 patients with metastatic renal carcinoma were referred to our Institute. One hundred and sixty-nine were included in immunotherapy protocols. The 40 most recent patients were included in the ongoing multicentric randomised Crecy study. The previous patients were treated with IL2...
journal_title:Bulletin du cancer
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1993-07-01 00:00:00
abstract::Newly synthesized dipyrido [4,3-b] [3,4-f] indole compounds have a structural similarity with the DNA intercalating agents ellipticines (pyrido-carbazoles). The procedure of synthesis of these compounds allows the addition of a lateral chain in position 1 of the nucleus. Comparison is made between different substituti...
journal_title:Bulletin du cancer
pub_type: 杂志文章
doi:
更新日期:1980-01-01 00:00:00